Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · IEX Real-Time Price · USD
58.00
-0.49 (-0.84%)
Mar 28, 2024, 1:46 PM EDT - Market open

Apellis Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018201720162015
Net Income
-528.63-652.17-746.35-344.87-304.71-127.5-51.01-27.12-46.52
Depreciation & Amortization
1.71.491.490.860.60000
Share-Based Compensation
105.9591.0970.6745.3821.147.735.421.080.55
Other Operating Activities
-173.7645.86111.07138.1571.83-11.47-1.010.0427.11
Operating Cash Flow
-594.74-513.75-563.13-160.49-211.14-131.24-46.6-26-18.86
Capital Expenditures
-0.67-1.52-1.1-5.42-1.690000
Change in Investments
061.42248.72-311.5700000
Investing Cash Flow
-0.6759.89247.62-316.99-1.690000
Share Issuance / Repurchase
461.04405.84398.02392.42112.71131.92150.7400
Debt Issued / Paid
000322.87184.21026.3600
Other Financing Activities
-66.54-40.18-5.79-23.1191.62-0.0220.2714.8641.23
Financing Cash Flow
394.5365.66392.24692.18388.54131.9197.3814.8641.24
Exchange Rate Effect
0.14-0.49-2.020.360-0.04000
Net Cash Flow
-200.78-88.6874.71215.06175.720.62150.78-11.1422.38
Free Cash Flow
-595.41-515.27-564.23-165.91-212.83-131.24-46.6-26-18.86
Free Cash Flow Margin
-150.13%-683.18%-847.66%-66.19%-----
Free Cash Flow Per Share
-5.02-4.86-6.68-2.21-3.42-2.41-3.36-3.08-3.25
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).